These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29326485)

  • 1. Orphan drugs: Indian perspective.
    Kumar H; Sarma P; Medhi B
    Indian J Pharmacol; 2017; 49(4):267-269. PubMed ID: 29326485
    [No Abstract]   [Full Text] [Related]  

  • 2. The study of drugs for rare disorders: harnessing research contributions by Canadian academic institutions.
    Macleod S; Lasko P; Mackenzie A
    J Popul Ther Clin Pharmacol; 2014; 21(1):e47-55. PubMed ID: 24671865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of academic institutions in the development of drugs for rare and neglected diseases.
    Coles LD; Cloyd JC
    Clin Pharmacol Ther; 2012 Aug; 92(2):193-202. PubMed ID: 22760003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orphan drug designation and development in Japan: 25 years of experience and assessment.
    Sakushima K; Takeda H; Aoi Y
    Nat Rev Drug Discov; 2021 Dec; 20(12):893-894. PubMed ID: 33723413
    [No Abstract]   [Full Text] [Related]  

  • 5. Neuromuscular disorders: orphan diseases deserve attention.
    de Visser M
    Lancet Neurol; 2006 Jan; 5(1):13-4. PubMed ID: 16361013
    [No Abstract]   [Full Text] [Related]  

  • 6. [Orphan drugs. Drugs for treatment of rare diseases].
    Hennemann A
    Med Monatsschr Pharm; 2004 Aug; 27(8):256-9. PubMed ID: 15382448
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug labels: a flawed source of data for studying orphan drug approvals.
    Kesselheim AS; Avorn J
    Clin Pharmacol Ther; 2012 Dec; 92(6):694; author reply 695. PubMed ID: 23073207
    [No Abstract]   [Full Text] [Related]  

  • 8. Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to?
    Harari S; Humbert M; Blasi F; Collard HR; Matucci-Cerinic M; Simonneau G; Vancheri C; Wells AU; Cottin V
    Eur Respir Rev; 2015 Sep; 24(137):375-7. PubMed ID: 26324798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study.
    Choudhury MC; Saberwal G
    Orphanet J Rare Dis; 2019 Nov; 14(1):241. PubMed ID: 31684990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crafting a robust business model for orphan drug development.
    Philippidis A
    Hum Gene Ther; 2011 Jul; 22(7):781-3. PubMed ID: 21756074
    [No Abstract]   [Full Text] [Related]  

  • 11. Challenges and Hurdles to Business as Usual in Drug Development for Treatment of Rare Diseases.
    Swinney DC
    Clin Pharmacol Ther; 2016 Oct; 100(4):339-41. PubMed ID: 27393380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [European incentives for orphan medicinal products].
    Enzmann H; Lütz J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Jumpstarting research into neglected diseases.
    Leslie M
    Cell; 2006 Nov; 127(3):443-5. PubMed ID: 17081963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The stakes of pre- and post-market authorization development and clinical assessment].
    Schwebig A
    Presse Med; 2012 May; 41 Suppl 1():S6-8. PubMed ID: 22483770
    [No Abstract]   [Full Text] [Related]  

  • 15. A new toolkit for conducting clinical trials in rare disorders: will this dog hunt?
    Peterson RG; Macleod SM; Klein AV
    J Popul Ther Clin Pharmacol; 2014; 21(1):e79-80. PubMed ID: 24671905
    [No Abstract]   [Full Text] [Related]  

  • 16. [Orphan diseases, rare diseases, time to get mobilised].
    Cordier JF
    Rev Prat; 2006 Jan; 56(2):123-4. PubMed ID: 16584035
    [No Abstract]   [Full Text] [Related]  

  • 17. A new era of hope for the world's most neglected diseases.
    The
    PLoS Med; 2005 Sep; 2(9):e323. PubMed ID: 16138790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flexibility in the FDA approach to orphan drug development.
    Hunter NL; Rao GR; Sherman RE
    Nat Rev Drug Discov; 2017 Nov; 16(11):737-738. PubMed ID: 28860647
    [No Abstract]   [Full Text] [Related]  

  • 19. Law and research could add up to profitable niche drugs.
    Haefner B
    Nature; 2007 Apr; 446(7138):856. PubMed ID: 17443162
    [No Abstract]   [Full Text] [Related]  

  • 20. [Orphan drugs: drugs for rare diseases].
    Schenk M
    Dtsch Med Wochenschr; 2010 May; 135(18):p17. PubMed ID: 20455291
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.